media coverage, page-2

Has anyone considered that GSK might eventually take BTA out?

Assuming BTA's case against GSK is successful, which is increasingly appearing more likely given recent Relenza sales, why on earth would GSK even consider paying-up?

GSK could buy BTA outright, including the royalties to Relenza and all cash on hand, as well as gaining exposure to their other prospects for about $400m...about the same amount as BTA are looking for as a settlement.

Unless BTA are happy to settle for a lot less than they are hoping for, it may turn out that BTA simply get swallowed up.

Cheers!